Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ringside For Zarxio At Supreme Court: Biosimilar Stakeholders Line Up

Executive Summary

High court set to determine timing of biosimilar marketing and how parties handle patent disputes in Sandoz v. Amgen. Stakeholders say the outcome will impact innovation, access to biosimilars and future litigation.


Related Content

Can Biosimilar Studies Be Conducted Solely In Healthy Volunteers?
Biosimilar Tentative Approvals Could Flow From US Supreme Court Case
FDA's Worst Case Scenario: Supreme Court Might Defer To It On Biosimilars
Biosimilars Podcast: What To Expect When Supreme Court Hears Amgen vs. Sandoz
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain
Biosimilar sponsors can avoid 'patent dance' in US, but innovators win extra exclusivity


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts